Monopar Therapeutics (NASDAQ:MNPR) Raised to “Hold” at Wall Street Zen

Monopar Therapeutics (NASDAQ:MNPRGet Free Report) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Thursday.

MNPR has been the subject of several other research reports. Piper Sandler reaffirmed an “overweight” rating and issued a $76.00 price target on shares of Monopar Therapeutics in a research report on Wednesday, March 19th. HC Wainwright reiterated a “buy” rating and issued a $40.00 price objective on shares of Monopar Therapeutics in a report on Tuesday, April 1st. Finally, Jones Trading reiterated a “hold” rating on shares of Monopar Therapeutics in a report on Wednesday, April 2nd. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $55.33.

View Our Latest Analysis on Monopar Therapeutics

Monopar Therapeutics Price Performance

MNPR opened at $35.45 on Thursday. The stock has a 50-day moving average price of $37.93 and a 200-day moving average price of $32.34. The firm has a market cap of $216.78 million, a PE ratio of -17.99 and a beta of 1.11. Monopar Therapeutics has a 1 year low of $1.72 and a 1 year high of $54.30.

Monopar Therapeutics (NASDAQ:MNPRGet Free Report) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.65) by $0.27. As a group, sell-side analysts anticipate that Monopar Therapeutics will post -1.65 EPS for the current year.

Insider Buying and Selling

In other Monopar Therapeutics news, major shareholder Tactic Pharma Llc sold 33,334 shares of the business’s stock in a transaction dated Wednesday, April 2nd. The stock was sold at an average price of $35.00, for a total transaction of $1,166,690.00. Following the completion of the sale, the insider now directly owns 822,255 shares in the company, valued at $28,778,925. The trade was a 3.90% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 20.50% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Monopar Therapeutics

A number of large investors have recently made changes to their positions in the company. Janus Henderson Group PLC bought a new stake in shares of Monopar Therapeutics during the 4th quarter valued at about $23,435,000. Adage Capital Partners GP L.L.C. bought a new stake in shares of Monopar Therapeutics during the 4th quarter valued at about $13,182,000. RA Capital Management L.P. bought a new stake in shares of Monopar Therapeutics during the 4th quarter valued at about $11,247,000. Point72 Asset Management L.P. bought a new stake in shares of Monopar Therapeutics during the 4th quarter valued at about $3,694,000. Finally, ADAR1 Capital Management LLC bought a new stake in shares of Monopar Therapeutics during the 4th quarter valued at about $2,861,000. 1.83% of the stock is currently owned by institutional investors.

About Monopar Therapeutics

(Get Free Report)

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.

Further Reading

Receive News & Ratings for Monopar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monopar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.